Targeting Cancer with ADCs | ADC Review ADC Review sorted by
relevance

Admin03.09.2021

Targeting Cancer with ADCs | ADC Review ADC Review

3700
Admin10.08.2021

Recommended Reading | ADC Review ADC Review

36010
Admin12.08.2021

Recommended Reading | ADC Review ADC Review

24010
Admin12.09.2021

biparatopic HER2-targeting antibody-drug conjugate

8404
Admin24.09.2021

Receptor-mediated endocytosis of a folate-drug conjugate

4004
Admin25.07.2021

Case Report: ADC Review | Journal of Antibody-drug

2402
Admin06.08.2021

Which of the following statements best describes receptor

Admin11.08.2021

Cynthia Wooge, Ph.D | ADC Review

79010
Admin19.08.2021

NCT01596218 | ADC Review

602
Admin16.08.2021

About Eric T. Rosenthal | Editor-at-Large » ADC Review

8407
Admin15.08.2021

Coming of Age: Antibody-drug Conjugates, Highly Targeted

Admin15.09.2021

NCT01969643 | ADC Review

Admin18.08.2021

NCT01700751 | ADC Review

9101
Admin17.08.2021

NCT02086604 | ADC Review

38010
Admin19.08.2021

Linkers for Antibody Drug Conjugates: Current Role and

1609
Admin02.09.2021

biparatopic HER2-targeting antibody-drug conjugate

3503
Admin11.08.2021

Single-layer Film Bags vs. Multi-layer Film Bags

3103
Admin16.09.2021

FDA Accepts Resubmission of Biologics License Application

2309
Admin30.07.2021

CD22-positive B-cell precursor acute lymphoblastic

9806
Admin30.07.2021

Duocarmazine » ADC Review

2606
Admin06.09.2021

SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily

2805